Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 3/2017

01-03-2017 | Tropical, Travel and Emerging Infections (L Chen, Section Editor)

Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day

Authors: Natalie D. Collins, Alan D. T. Barrett

Published in: Current Infectious Disease Reports | Issue 3/2017

Login to get access

Abstract

Purpose of Review

Live attenuated 17D vaccine is considered one of the safest and efficacious vaccines developed to date. This review highlights what is known and the gaps in knowledge of vaccine-induced protective immunity.

Recent Findings

Recently, the World Health Organization modifying its guidance from 10-year booster doses to one dose gives lifelong protection in most populations. Nonetheless, there are some data suggesting immunity, though protective, may wane over time in certain populations and more research is needed to address this question. Despite having an effective vaccine to control yellow fever, vaccine shortages were identified during outbreaks in 2016, eventuating the use of a fractional-dosing campaign in the Democratic Republic of the Congo.

Summary

Limited studies hinder identification of the underlying mechanism(s) of vaccine longevity; however, concurrent outbreaks during 2016 provide an opportunity to evaluate vaccine immunity following fractional dosing and insights into vaccine longevity in populations where there is limited information.
Literature
1.
2.
•• Garske T, Van Kerkhove MD, Yactayo S, Olivier R, Lewis RF, Staples JE, et al. Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Med. 2014;11:e1001638. The most current morbidity and mortality rates of yellow fever virus in Africa.CrossRefPubMedPubMedCentral
3.
Barrett AD, Higgs S. Yellow fever: a disease that has yet to be conquered. Annu Rev Entomol. 2007;52:209–29.CrossRefPubMed
4.
Lai S, Huang Z, Zhou H, Anders KL, Perkins TA, Yin W, et al. The changing epidemiology of dengue in China, 1990–2014: a descriptive analysis of 25 years of nationwide surveillance data. BMC Med. 2015;13:100.CrossRefPubMedPubMedCentral
5.
Bryant JE, Holmes EC, Barrett AD. Out of Africa: a molecular perspective on the introduction of yellow fever virus into the Americas. PLoS Pathog. 2007;3, e75.CrossRefPubMedPubMedCentral
6.
Beck A, Guzman H, Li L, et al. Phylogeographic reconstruction of African yellow fever virus isolates indicates recent simultaneous dispersal into east and west Africa. PLoS Negl Trop Dis. 2013;7, e1910.CrossRefPubMedPubMedCentral
7.
8.
9.
Pugachev KV, Guirakhoo F, Ocran SW, Mitchell F, Parsons M, Penal C, et al. High fidelity of yellow fever virus RNA polymerase. J Virol. 2004;78:1032–8.CrossRefPubMedPubMedCentral
10.
Beck A, Tesh RB, Wood TG, Widen SG, Ryman KD, Barrett AD. Comparison of the live attenuated yellow fever vaccine 17D-204 strain to its virulent parental strain Asibi by deep sequencing. J Infect Dis. 2014;209:334–44.CrossRefPubMed
11.
Tangy F, Desprès P. Yellow fever vaccine attenuation revealed: loss of diversity. J Infect Dis. 2014;209:318–20.CrossRefPubMed
12.
Salmona M, Gazaigne S, Mercier-Delarue S, Garnier F, Korimbocus J, de Verdière NC, et al. Molecular characterization of the 17D-204 yellow fever vaccine. Vaccine. 2015;33:5432–6.CrossRefPubMed
13.
14.
Barrett AD, Teuwen DE. Yellow fever vaccine—how does it work and why do rare cases of serious adverse events take place? Curr Opin Immunol. 2009;21:308–13.CrossRefPubMed
15.
Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, Filali-Mouhim A, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med. 2008;205:3119–31.CrossRefPubMedPubMedCentral
16.
Luiza-Silva M, Campi-Azevedo AC, Batista MAA, Martins MA, Avelar RS, da Silveira D, et al. Cytokine signatures of innate and adaptive immunity in 17DD yellow fever vaccinated children and its association with the level of neutralizing antibody. J Infect Dis. 2011;204:873–83.CrossRefPubMed
17.
Silva ML, Martins MA, Espírito-Santo LRR, Campi-Azevedo AC, Silveira-Lemos D, Ribeiro JGG, et al. Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults. Vaccine. 2011;29:583–92.CrossRefPubMed
18.
Quaresma JA, Pagliari C, Medeiros DB, Medeiros DB, Duarte MI, Vasconcelos PF. Immunity and immune response, pathology and pathologic changes: progress and challenges in the immunopathology of yellow fever. Rev Med Virol. 2013;23:305–18.CrossRefPubMed
19.
Gotuzzo E, Yactayo S, Córdova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013;89:434–44.CrossRefPubMedPubMedCentral
20.
Blom K, Braun M, Ivarsson MA, Gonzalez VD, Falconer K, Moll M, et al. Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response. J Immunol. 2013;190:2150–8.CrossRefPubMed
21.
• Watson AM, Lam LK, Klimstra WB, Ryman KD. The 17D-204 vaccine strain-induced protection against virulent yellow fever virus is mediated by humoral immunity and CD4+ but not CD8+ T cells. PLoS Pathog. 2016;12:e1005786. An in vivo mouse study that details the immune response following vaccination with 17D-204 which suggest cellular immunity, specifically, CD4 cells contribute to protection from wild-type infection.CrossRefPubMedPubMedCentral
22.
James EA, LaFond RE, Gates TJ, Mai DT, Malhotra U, Kwok WW. Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins. J Virol. 2013;87:12794–804.CrossRefPubMedPubMedCentral
23.
Wieten RW, Goorhuis A, Jonker EFF, de Bree GJ, de Visser AW, van Genderen JJ, et al. 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients. J Infect. 2016;72:713–22.CrossRefPubMed
24.
Fuertes Marraco SA, Soneson C, Cagnon L, Gannon PO, Allard M, Maillard SA, et al. Long-lasting stem cell-like memory CD8+ T cells with a naïve-like profile upon yellow fever vaccination. Sci Transl Med. 2015;7:282ra48.CrossRefPubMed
25.
Akondy RS, Johnson PL, Nakaya HI, Edupuganti S, Mulligan MJ, Lawson B, et al. Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination. Proc Natl Acad Sci U S A. 2015;112:3050–5.CrossRefPubMedPubMedCentral
26.
Staples JE, Gershman M, Fischer M. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59:1–27.
27.
Collaborative group for studies on yellow fever vaccines. Duration of post-vaccination immunity against yellow fever in adults. Vaccine. 2014;32:4977–84.CrossRef
28.
Campi-Azevedo AC, Costa-Pereira C, Antonelli LR, Fonseca CT, Teixeira-Carvalho A, Villela-Rezende G, et al. Booster dose after 10 years is recommended following 17DD-YF primary vaccination. Hum Vaccin Immunother. 2016;12:491–502.CrossRefPubMed
29.
De Melo AB, da Paz MC, Magalhães M. Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. AmJTrop Med Hyg. 2011;85(4):739–47.CrossRefPubMedPubMedCentral
30.
Hepburn MJ, Kortepeter MG, Pittman PR, Boudreau EF, Mangiafico JA, Buck PA, et al. Neutralizing antibody response to booster vaccination with the 17D yellow fever vaccine. Vaccine. 2006;24:2843–9.CrossRefPubMed
31.
Muyanja E, Ssemaganda A, Ngauv P, Cubas R, Perrin H, Srinivasan D, et al. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. J Clin Invest. 2014;124:3147–58.CrossRefPubMedPubMedCentral
32.
Jean K, Donnelly C, Ferguson N, Garske T. A Meta-analysis of serological response associated with yellow fever vaccination. Am J Trop Med Hyg. 2016;95(6):1435–9.CrossRefPubMedPubMedCentral
33.
Amanna IJ, Slifka MK. Questions regarding the safety and duration of immunity following live yellow fever vaccination. Expert Rev Vaccines. 2016;15:1519–33.CrossRefPubMed
34.
35.
Grobbelaar AA, Weyer J, Moolla N, van Vuren PJ, Moises F, Paweska JT. Resurgence of yellow fever in Angola, 2015–2016. Emerg Infect Dis. 2016;22:1854–5.CrossRefPubMedPubMedCentral
36.
•Barrett AD. Yellow fever in Angola and beyond—the problem of vaccine supply and demand. N Engl J Med. 2016;375:301–3. Discusses 17D vaccine production and formulation, as well as, alternative approaches to vaccination storages due to the Angola and concurrent outbreaks.CrossRefPubMed
37.
38.
39.
40.
41.
42.
•• Campi-Azevedo AC, de Almeida EP, Coelho-Dos-Reis JG, Peruhype-Magalhães V, Willela-Rezende G, Quaresma PFF, et al. Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline. BMC Infect Dis. 2014;14:391. Follow-up to Martins et al. [43] study that undertakes a detailed study of the innate and adaptive immune response following sub-dose vaccination with 17DD. CrossRefPubMedPubMedCentral
43.
•• Martins RM, de Maia ML, Farias RH, Camacho LA, Freire MS, Galler R, et al. 17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study. Hum Vaccin Immunother. 2013;9:879–88. Study of fractional dosing with 17DD sub-strain, concluding that subdoses as low as 587 IU induced comparable nuetralizing antibodies as a single dose.CrossRefPubMedPubMedCentral
44.
Metadata
Title
Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day
Authors
Natalie D. Collins
Alan D. T. Barrett
Publication date
01-03-2017
Publisher
Springer US
Published in
Current Infectious Disease Reports / Issue 3/2017
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-017-0566-9

Other articles of this Issue 3/2017

Current Infectious Disease Reports 3/2017 Go to the issue

Cardiovascular Infections (B Hoen, Section Editor)

Indications of Surgery in Infective Endocarditis

Respiratory Infections (F Arnold, Section Editor)

Enterovirus D68-Associated Community-Acquired Pneumonia in the Pediatric Age Group

Respiratory Infections (F Arnold, Section Editor)

Risk Factors for Drug-Resistant Cap in Immunocompetent Patients

Central Nervous System Infections (K Bloch, Section Editor)

Herpes Simplex Encephalitis: an Update
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits